Q-omics provides the consensus-scored FAM53A profile across patient tissues and cancer cell-line models. FAM53A expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FAM53A is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, FAM53A RNA expression shows 18,817 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and LUAD as cancer lineages where FAM53A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM53A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM53A survival associations across molecular data types. FAM53A RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM53A RNA expression–survival associations across cancer types. High FAM53A expression shows unfavorable associations in UVM, KIRC, KICH, LIHC and LGG, but favorable associations in UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for FAM53A RNA expression.
This table summarizes FAM53A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for FAM53A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM53A shows lower tumor expression in THCA and KICH and higher tumor expression in LUAD, COAD, LIHC and READ. The LUAD box plot shows higher FAM53A RNA expression in tumor versus normal tissue (log2 FC = +0.592, t-test p < 0.001).
This table shows molecular features associated with FAM53A in patient tissues and cancer cell lines. In patient samples, FAM53A shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM53A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
